Literature DB >> 8842259

Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance.

J P Steinberg1, C C Clark, B O Hackman.   

Abstract

The rate of nosocomial bacteremia due to Staphylococcus aureus has increased over the past decade, but trends in community-acquired S. aureus bacteremia are less certain. This hospital-based observational study compares nosocomial and community-acquired S. aureus bacteremias during 1980-1983 and 1990-1993. The rate of nosocomial S. aureus bacteremia increased from 0.75 to 2.80 cases per 1,000 discharges, while the rate of community-acquired S. aureus bacteremia increased from 0.84 to 2.43 cases per 1,000 discharges. The number of nosocomial device-related bacteremias increased eightfold; 56% of S. aureus bacteremias were associated with devices during 1990-1993. Intravascular devices were associated with no community-acquired S. aureus bacteremias during 1980-1983 but with 22% during 1990-1993. Methicillin-resistant S. aureus (MRSA) seldom caused bacteremia during 1980-1983. From 1990 to 1993, MRSA caused 32% and 18.5% of nosocomial and community-acquired S. aureus bacteremias, respectively. The rates of both community-acquired and nosocomial S. aureus bacteremias have increased significantly since 1980. In addition to their role in nosocomial infections, MRSA and intravascular device-related S. aureus bacteremias are emerging problems in the nonhospital setting.

Entities:  

Mesh:

Year:  1996        PMID: 8842259     DOI: 10.1093/clinids/23.2.255

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  69 in total

1.  Echocardiography for the Diagnosis of Staphylococcus aureus Infective Endocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

2.  Population genomics in bacteria: a case study of Staphylococcus aureus.

Authors:  Shohei Takuno; Tomoyuki Kado; Ryuichi P Sugino; Luay Nakhleh; Hideki Innan
Journal:  Mol Biol Evol       Date:  2011-10-17       Impact factor: 16.240

3.  Clonal distribution and phase-variable expression of a major histocompatibility complex analogue protein in Staphylococcus aureus.

Authors:  Angus Buckling; James Neilson; Jodi Lindsay; Richard ffrench-Constant; Mark Enright; Nicholas Day; Ruth C Massey
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

4.  Classifying spa types in complexes improves interpretation of typing results for methicillin-resistant Staphylococcus aureus.

Authors:  Werner Ruppitsch; Alexander Indra; Anna Stöger; Barbara Mayer; Silke Stadlbauer; Günther Wewalka; Franz Allerberger
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

5.  Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus.

Authors:  Melanie R Stapleton; Malcolm J Horsburgh; Emma J Hayhurst; Lynda Wright; Ing-Marie Jonsson; Andrej Tarkowski; John F Kokai-Kun; James J Mond; Simon J Foster
Journal:  J Bacteriol       Date:  2007-08-03       Impact factor: 3.490

6.  What do central venous catheter-associated bloodstream infections have to do with bundles?g.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

7.  Staphylococcus aureus: The persistent pathogen.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2003-11

8.  Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Authors:  J John Weems; James P Steinberg; Scott Filler; John W Baddley; G Ralph Corey; Priya Sampathkumar; Lisa Winston; Joseph F John; Christine J Kubin; Rohit Talwani; Thomas Moore; Joseph M Patti; Seth Hetherington; Michele Texter; Eric Wenzel; Violet A Kelley; Vance G Fowler
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

9.  Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Authors:  Kevin E Chan; H Shaw Warren; Ravi I Thadhani; David J R Steele; Jeffrey L Hymes; Franklin W Maddux; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

10.  Is methicillin-resistant Staphylococcus aureus an emerging community pathogen? A review of the literature.

Authors:  M A Gardam
Journal:  Can J Infect Dis       Date:  2000-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.